Towards a prognostic glycogene expression signature for melanoma patients”

JOAQUÍN P MERLO; MAHMOUD, YD.; VEIGAS, F.; MARIÑO, KV.; GIROTTI, MR.

Buenos Aires

Simposio; 5to Simposio Argentino de Jovenes Investigadores en Bioinformatica; 2020

RSG Argentina

​Melanoma is the deadliest form of skin cancer and the incidence will continue to increase. Until recently, first line of treatment was a set of targeted therapies, but since the approval of immunotherapies in 2010, there has been a paradigm shift within the area. This therapeutic strategy targets Immune Checkpoints and unleashes anti-tumor immunity by impeding immune-suppressive mechanisms, considerably improving survival rates. However, and considering that around 50% of patients show intrinsic resistance, further delving into different pathways becomes indispensable to characterize novel biomarkers, improved tools for diagnostic and accurate clinical decisions.In this work, we studied the glycol-immune pathways that may be involved in resistance to immunotherapies. Metastatic biopsies from SKCM project of The Cancer Genome Atlas (TCGA) were clustered using the 10% most variable genes (n=78) from a set of 834 glycogenes, resulting in two different clusters of patients with significantly different overall survival (p